Several studies demonstrate that combinatorial approaches (for instance, DAC + HDAC inhibitors, DAC + immune checkpoint blockade) can partially overcome these mechanisms by reactivating silenced tumor suppressors and enhancing immunogenicity [62,63,65]. Here, HDAC9 is linked to neoplasm.